Does Meropenem Cause Neutropenia?
Yes, meropenem can cause neutropenia, though this is an uncommon adverse effect. This hematologic abnormality is documented in FDA labeling and case reports, but occurs rarely in clinical practice 1.
Evidence from FDA Drug Labeling
The FDA-approved prescribing information for meropenem explicitly lists hematologic adverse reactions, including decreased white blood cell count and leukocytosis among laboratory changes occurring in greater than 0.2% of patients 1. The drug label warns about thrombocytopenia in patients with renal impairment, though no clinical bleeding has been reported 1. While the label doesn't specifically quantify neutropenia incidence, it acknowledges hematologic monitoring is warranted.
Clinical Evidence and Incidence
Recent case reports confirm meropenem-induced neutropenia occurs in real-world practice:
- A 2024 case report documented neutropenia induced by both ceftriaxone and meropenem, with resolution within 48 hours of discontinuation 2
- A 2021 neonatal case showed severe pancytopenia (ANC 816 cells/mm³) developing on day 17 of therapy, with recovery beginning 4 days after stopping meropenem 3
- A 2016 pediatric case reported isolated neutropenia (ANC 288 cells/mm³) on day 14 of treatment, resolving 2 months after discontinuation 4
The mortality rate from antibiotic-induced neutropenia ranges from 2.5-5%, though deaths remain rare 2.
Important Clinical Context
The guidelines for febrile neutropenia management recommend meropenem as first-line empiric therapy for high-risk neutropenic patients 5. This creates a clinical paradox: meropenem is used to treat infections in neutropenic patients, yet can rarely cause neutropenia itself.
The guidelines make no mention of meropenem causing neutropenia as a concern, focusing instead on its efficacy and safety profile compared to other beta-lactams 5. This suggests the risk is sufficiently low that it doesn't alter treatment recommendations.
Monitoring Recommendations
For patients receiving prolonged meropenem courses (>14 days) or high doses, monitor complete blood counts regularly:
- Baseline CBC before initiating therapy
- Weekly CBC monitoring during extended treatment
- More frequent monitoring in neonates and patients with renal impairment 3, 4
Management if Neutropenia Develops
If neutropenia occurs during meropenem therapy:
- Discontinue meropenem immediately if no alternative explanation exists
- Expect recovery within 2-7 days after discontinuation 2, 3
- Consider G-CSF administration to accelerate recovery, particularly if patient becomes febrile or septic 2
- Switch to alternative antibiotic based on culture data and local resistance patterns
- Monitor neutrophil counts daily until recovery to >1500 cells/mm³
Key Caveats
- The exact incidence in adults and children remains unknown due to limited surveillance data 3, 4
- Neonates may be at higher risk and require more vigilant monitoring 3, 4
- Patients with renal impairment show increased risk of hematologic abnormalities 1
- Do not withhold meropenem in life-threatening infections due to neutropenia risk—the benefit far outweighs this rare adverse effect
The clinical bottom line: while meropenem can cause neutropenia, this idiosyncratic reaction is sufficiently rare that it should not deter appropriate use in serious infections, but does warrant CBC monitoring during prolonged therapy.